These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21701442)

  • 1. Ipilimumab (Yervoy) for metastatic melanoma.
    Med Lett Drugs Ther; 2011 Jun; 53(1367):51-2. PubMed ID: 21701442
    [No Abstract]   [Full Text] [Related]  

  • 2. Ipilimumab (Yervoy) and inoperable or metastatic melanoma. More evaluation needed, in both first- and second-line use.
    Prescrire Int; 2015 Apr; 24(159):96. PubMed ID: 25941700
    [No Abstract]   [Full Text] [Related]  

  • 3. Ipilimumab: a novel treatment for metastatic melanoma.
    Culver ME; Gatesman ML; Mancl EE; Lowe DK
    Ann Pharmacother; 2011 Apr; 45(4):510-9. PubMed ID: 21505108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab: showing survival benefit in metastatic melanoma.
    Minchom A; Young K; Larkin J
    Future Oncol; 2011 Nov; 7(11):1255-64. PubMed ID: 22044200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab (Opdivo) plus ipilimumab (Yervoy) for metastatic melanoma.
    Med Lett Drugs Ther; 2015 Dec; 57(1483):168. PubMed ID: 26633687
    [No Abstract]   [Full Text] [Related]  

  • 7. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
    Hanaizi Z; van Zwieten-Boot B; Calvo G; Lopez AS; van Dartel M; Camarero J; Abadie E; Pignatti F
    Eur J Cancer; 2012 Jan; 48(2):237-42. PubMed ID: 22030452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma.
    Del Vecchio M; Mortarini R; Tragni G; Di Guardo L; Bersani I; Di Tolla G; Agustoni F; Colonna V; Weber JS; Anichini A
    J Clin Oncol; 2011 Nov; 29(32):e783-8. PubMed ID: 21990398
    [No Abstract]   [Full Text] [Related]  

  • 9. Ipilimumab, a human monoclonal antibody for treatment of unresectable or metastatic melanoma.
    Wilkes GM
    Oncology (Williston Park); 2011 Jul; 25(7 Suppl Nurse Ed):46-7. PubMed ID: 25373277
    [No Abstract]   [Full Text] [Related]  

  • 10. [Major therapeutic advances in the treatment of metastatic melanoma].
    Mateus C; Robert C
    Bull Cancer; 2012 Jun; 99(6):619-25. PubMed ID: 22652330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab in advanced melanoma: reports of long-lasting responses.
    Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
    Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma.
    Tarhini AA; Kirkwood JM
    Oncology (Williston Park); 2010 Dec; 24(14):1302, 1304. PubMed ID: 21294474
    [No Abstract]   [Full Text] [Related]  

  • 13. Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma.
    Burke MM; Kluger HM; Golden M; Heller KN; Hoos A; Sznol M
    J Clin Oncol; 2011 Nov; 29(32):e792-4. PubMed ID: 21990407
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel therapies for the treatment of metastatic melanoma.
    Chouake J; Friedman A
    J Drugs Dermatol; 2012 Feb; 11(2):271-3. PubMed ID: 22270215
    [No Abstract]   [Full Text] [Related]  

  • 15. Ipilimumab for advanced melanoma: let's not throw caution to the winds.
    Lowe M; Delman KA
    Oncology (Williston Park); 2010 Dec; 24(14):1296, 1299. PubMed ID: 21294473
    [No Abstract]   [Full Text] [Related]  

  • 16. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma.
    Bernardo SG; Moskalenko M; Pan M; Shah S; Sidhu HK; Sicular S; Harcharik S; Chang R; Friedlander P; Saenger YM
    Melanoma Res; 2013 Feb; 23(1):47-54. PubMed ID: 23262440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
    Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?
    Dick J; Enk A; Hassel JC
    Dermatology; 2015; 230(1):8-10. PubMed ID: 25531526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diarrhea from ipilimumab in melanoma.
    Schwartz JD
    N Engl J Med; 2010 Dec; 363(23):2262; author reply 2262-3. PubMed ID: 21121842
    [No Abstract]   [Full Text] [Related]  

  • 20. Ipilimumab activity in advanced uveal melanoma.
    Khattak MA; Fisher R; Hughes P; Gore M; Larkin J
    Melanoma Res; 2013 Feb; 23(1):79-81. PubMed ID: 23211837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.